Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ – STARS Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc Raises FY 2013 Guidance

Thursday, 24 Oct 2013 06:30am EDT 

Alexion Pharmaceuticals Inc announced that it is raising its fiscal 2013 revenue guidance from the previous range of $1.520 to $1.530 billion, now to the higher and narrower range of $1.535 to $1.540 billion. The upward revision reflects continued global growth of Soliris in PNH and growth from the ongoing launch of Soliris in aHUS. Non-GAAP EPS is also being revised upward, from the previous range of $2.97 to $3.02, now to the higher and narrower range of $3.02 to $3.04, based on a forecast of approximately 203 million diluted shares outstanding. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.530 billion and EPS of $3.03 for fiscal 2013. 

Company Quote

6 Jul 2015